Literature DB >> 31808849

Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor-associated major bleeding.

Miriam Kimpton1, Deborah M Siegal2.   

Abstract

A 77-year-old man with atrial fibrillation and a CHA2DS2Vasc score of 6 for hypertension, age, diabetes, and previous stroke is brought to the emergency department with decreased level of consciousness. He is anticoagulated with rivaroxaban (a direct oral factor Xa inhibitor [FXaI]) and received his last dose about 4 hours before presentation. Urgent computed tomography of the head shows intracerebral hemorrhage. Because of his previous stroke, the patient's family is concerned about treating the bleed with pharmacological agents that may increase the risk of stroke. What are the risks of thrombosis and mortality related to the use of prothrombin complex concentrates (PCCs) and andexanet alfa for patients with direct oral FXaI-associated major bleeding?
© 2019 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31808849      PMCID： PMC6913461          DOI： 10.1182/hematology.2019000074

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


  20 in total

1.  Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding.

Authors:  Deepa R J Arachchillage; Sharon Alavian; Jessica Griffin; Kamala Gurung; Richard Szydlo; Nilanthi Karawitage; Mike Laffan
Journal:  Br J Haematol       Date:  2018-12-04       Impact factor: 6.998

2.  Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH.

Authors:  N Khorsand; A Majeed; R Sarode; J Beyer-Westendorf; S Schulman; K Meijer
Journal:  J Thromb Haemost       Date:  2015-10-27       Impact factor: 5.824

3.  Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.

Authors:  Stuart J Connolly; Mark Crowther; John W Eikelboom; C Michael Gibson; John T Curnutte; John H Lawrence; Patrick Yue; Michele D Bronson; Genmin Lu; Pamela B Conley; Peter Verhamme; Jeannot Schmidt; Saskia Middeldorp; Alexander T Cohen; Jan Beyer-Westendorf; Pierre Albaladejo; Jose Lopez-Sendon; Andrew M Demchuk; Daniel J Pallin; Mauricio Concha; Shelly Goodman; Janet Leeds; Sonia Souza; Deborah M Siegal; Elena Zotova; Brandi Meeks; Sadia Ahmad; Juliet Nakamya; Truman J Milling
Journal:  N Engl J Med       Date:  2019-02-07       Impact factor: 91.245

4.  Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study.

Authors:  Ammar Majeed; Anna Ågren; Margareta Holmström; Maria Bruzelius; Roza Chaireti; Jacob Odeberg; Eva-Lotta Hempel; Maria Magnusson; Tony Frisk; Sam Schulman
Journal:  Blood       Date:  2017-08-23       Impact factor: 22.113

5.  Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis.

Authors:  Francesco Dentali; Chiara Marchesi; Matteo Giorgi Pierfranceschi; Mark Crowther; David Garcia; Elaine Hylek; Daniel M Witt; Nathan P Clark; Alessandro Squizzato; Davide Imberti; Walter Ageno
Journal:  Thromb Haemost       Date:  2011-07-28       Impact factor: 5.249

Review 6.  Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis.

Authors:  Siavash Piran; Rasha Khatib; Sam Schulman; Ammar Majeed; Anne Holbrook; Daniel M Witt; Wojtek Wiercioch; Holger J Schünemann; Robby Nieuwlaat
Journal:  Blood Adv       Date:  2019-01-22

7.  Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage.

Authors:  Daniel Dybdahl; Grant Walliser; M Chance Spalding; Michelle Pershing; Michelle Kincaid
Journal:  Am J Emerg Med       Date:  2019-01-09       Impact factor: 2.469

8.  Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study.

Authors:  Sam Schulman; Peter L Gross; Bruce Ritchie; Susan Nahirniak; Yulia Lin; Lani Lieberman; Marc Carrier; Mark A Crowther; Indy Ghosh; Alejandro Lazo-Langner; Michelle Zondag
Journal:  Thromb Haemost       Date:  2018-03-21       Impact factor: 5.249

9.  Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists.

Authors:  Martin Müller; Jonathan Eastline; Michael Nagler; Aristomenis K Exadaktylos; Thomas C Sauter
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2019-04-23       Impact factor: 2.953

10.  Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial.

Authors:  Bettina Schenk; Stephanie Goerke; Ronny Beer; Raimund Helbok; Dietmar Fries; Mirjam Bachler
Journal:  Thromb J       Date:  2018-01-10
View more
  1 in total

1.  A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors.

Authors:  Ophira Salomon; David Gailani
Journal:  J Thromb Haemost       Date:  2021-11-21       Impact factor: 16.036
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.